During the past decade extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae have become a matter of great concern in human and veterinary medicine. In this cross-sectional study fecal swabs of a geographically representative number of Swiss cattle at slaughterhouse level were sampled i) to determine the occurrence of ESBL producing Enterobacteriaceae in the Swiss slaughter cattle population younger than 2 years, and ii) to assess risk factors for shedding ESBL producing Enterobacteriaceae. In total, 48 (8.4%; 95% C.I. 6.3–11.1%) independent ESBL producing Enterobacteriaceae were detected among the 571 tested animals. Species identification revealed 46 E. coli strains, one Enterobacter cloacae and one Citrobacter youngae. In view of beta-lactam antibiotics, all 48 isolates were resistant to ampicillin, cephalothin and cefpodoxime. Forty-five (93.8%) isolates were resistant cefuroxime; one (2.1%) isolate to cefoxitin, 28 (58.3%) isolates to cefotaxime, 2 (4.2%) isolates to ceftazidime, and 2 (4.2%) isolates to cefepime. Risk factors for shedding ESBL producing Enterobacteriaceae were (i) age (OR 0.19 and 0.12 in age category 181 d to 1y and 1y to 2 y compared to ≤180 d), (ii) primary production type, meaning dairy compared to beef on farm of origin (OR 5.95), and (iii) more than 1 compared to less than 1 animal movement per d per 100 animals on farm of origin (OR 2.37).
Citation: Reist M, Geser N, Hächler H, Schärrer S, Stephan R (2013) ESBL-Producing Enterobacteriaceae: Occurrence, Risk Factors for Fecal Carriage and Strain Traits in the Swiss Slaughter Cattle Population Younger than 2 Years Sampled at Abattoir Level. PLoS ONE 8(8): e71725. https://doi.org/10.1371/journal.pone.0071725
Editor: Odir A. Dellagostin, Federal University of Pelotas, Brazil
Received: May 14, 2013; Accepted: July 9, 2013; Published: August 20, 2013
Copyright: © 2013 Reist et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by the Swiss Federal Veterinary Office (FVO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Antimicrobial resistance in bacteria has emerged as a problem in both human and veterinary medicine. One of the currently most important resistance mechanisms in Enterbacteriaceae, which reduces the efficacy even of modern expanded-spectrum cephalosporins (except cephamycins and carbapenems) and monobactams is based on plasmid-mediated production of enzymes that inactivate these compounds by hydrolyzing their beta-lactam ring. Such resistance is encoded by an increasing number of different point-mutational variants, called extended spectrum beta-lactamases (ESBL), of classical broad-spectrum beta-lactamases (BSBL): most are derivates of TEM and SHV beta-lactamase families, whereas other groups, such as CTX-M, OXA, PER and VEB beta-lactamases have been described more recently . The phenotypical difference between BSBLs and ESBLs is that the latter efficiently hydrolyze 3rd- and 4th-generation cephalosporins, in addition to penicillins and 1st and 2nd generation cephalosporins as the BSBLs are capable of. ESBLs are inhibited by clavulanic acid, sulbactam and tazobactam , a feature that is used (i) as a criterion for classification of β-lactamases and (ii) for diagnostic ESBL detection purposes. As a matter of growing concern, resistance caused by ESBLs is often associated with resistance to other classes of antibiotics like fluoroquinolones, aminoglycosides and trimethoprim-sulfamethoxazole , .
Since the first description of ESBL producing Enterobacteriaceae isolated from hospitalized humans , many nosocomial outbreaks have been reported. However, since a few years, there is an increase in the detection of ESBL producing strains in the community , . More recently, some reports have alerted about the dissemination of ESBL producing E. coli in healthy cattle in several countries in Europe and USA , ,  or in cattle derived food products like meat and raw milk , , . Therefore, the impact of healthy farm animals as a reservoir for an input of ESBL producing E. coli in the food processing chain has to be assessed.
The aim of the present study was to assess the prevalence of ESBL producing Enterobacteriaceae in the Swiss cattle population younger than two years, and to assess risk factors for shedding ESBL producing Enterobacteriaceae based on a slaughterhouse monitoring approach that is aiming at achieving a geographically representative sample. Whilst for monitoring purposes a geographically representative set is easily achieved for samples taken on a farm level, where farms to be sampled can be determined in advance by applying a stratified randomization scheme, this is typically more difficult for samples taken at the slaughterhouse.
Materials and Methods
Representative samples for the cattle population younger than 2 years were taken at the slaughterhouse level. A minimum required sample size of 385 randomly selected animals was calculated with the assumptions of an infinite population size, a prevalence of 50%, a desired confidence level of 95.0% and an absolute error of 5% (Win Episcope 2.0 software http://www.clive.ed.ac.uk/winepiscope). The samples were randomly taken at the five biggest cattle abattoirs (A: Zurich; B: Hinwil; C: St. Gallen; D: Oensingen; E: Estavayer-le-Lac), where over 75% of Swiss cattle of the targeted age group are slaughtered. Because animals originating from farms located south of the Alps are typically underrepresented in the slaughter population of these 5 biggest abattoirs, samples from the biggest abattoir in the canton of Ticino (F: Bellinzona) and samples from several smaller abattoirs from the canton of Valais were additionally collected to guarantee a geographically representative distribution. From all the abattoirs we obtained the permission to use these animal parts.
Only one sample was taken per animal holding of origin. The number of samples in the sampling frame collected from each slaughterhouse was proportional to the number of cattle slaughtered at each establishment per year. Based on these data, a random sampling plan was conceived.
Faecal swabs were collected from November 2010 to September 2011 from 571 healthy animals younger than 2 years at slaughter. These animals had no contact to older cattle populations on the transport to the slaughterhouse, in the slaughterhouse or during the slaughtering procedure. Therefore, contamination by animals of older age classes after having left the farm of origin can be excluded. The samples were taken through opening the large intestine with sterile scissors after evisceration. Unique animal identification numbers registered in the Swiss central animal movement database (AMD) were recorded.
Each swab was incubated for 24 hours at 37°C in 10 ml EE Broth (BD, Franklin Lakes, USA) for enrichment. One loop of the enriched faecal samples were inoculated onto Brilliance ESBL agar (Oxoid, Hampshire, UK) and incubated at 37°C for 24 hours under aerobic conditions. All grown colonies were selected and sub-cultured onto Triple Sugar Iron (TSI) agar (BD, Franklin Lakes, USA) at 37°C for 24 hours. By the oxidase test and the assessment of lactose fermentation, non-fermenters were discarded, and oxidase-negative colonies were subjected to identification by API ID 32 E (bioMérieux, Marcy l'Etoile, France).
Antimicrobial susceptibility testing and ESBL detection
All isolated strains were subjected to susceptibility testing for 18 antimicrobial agents by the disc diffusion method and evaluated according to CLSI criteria . Strains exhibiting intermediate resistance were classified as susceptible. The antibiotics tested were: ampicillin (AM, 10 μg), amoxicillin/clavulanic acid (AMC, 20/10 μg), cephalothin (CF, 30 μg), cefuroxime (CXM, 30 μg), cefoxitin (FOX, 30 μg), cefpodoxime (CPD, 10 μg), cefotaxime (CTX, 30 μg), ceftazidime (CAZ, 30 μg), cefepime (FEP, 30 μg), ciprofloxacin (CIP, 5 μg), nalidixic acid (NA, 30 μg), gentamicin (GM, 10 μg), streptomycin (S, 10 μg), trimethoprim-sulfamethoxazole (SXT, 1.25/23.75 μg), chloramphenicol (C, 30 μg) and tetracycline (TE, 30 μg). The amoxicillin/clavulanic acid disc was placed between the cefpodoxime and the ceftazidime discs, and the synergy effect was documented. The strains, which showed a synergy effect, were then confirmed as ESBL producers on Muller-Hinton agar plates using E-Test-ESBL strips containing cefotaxime, cefepime or ceftazidime alone and in combination with clavulanic acid (bioMérieux, Marcy l'Etoile, France).
Risk Factor Analysis
Risk factors were calculated based on data obtained from the Swiss AMD. The individual animal identification number of the slaughtered and sampled animals served as a unique identifier to determine the farm of origin, date of birth and to access all incoming movement data corresponding to the farm of origin and the length of stay of each individual animal of the sample. Risk factors derived from AMD data comprised age, main production type on the farm of origin (dairy vs. beef and fattening), farm size, number of animal movements and number of animals found death or euthanized on farm. The full list of studied risk factors and their categorization is given in Table 1.
Statistical analyses were performed in R version 2.13 for Mac OS. The significance level was set at p≤0.05. ESBL prevalence and their Yates' continuity corrected 95% confidence intervals were calculated applying exact binomial tests. Logistic regression models were applied for risk factor analyses. First, a univariate model was calculated for each risk factor given in Table 1. Risk factors with a p-value <0.25 were retained for multivariate analyses. To avoid colinearity, the correlation structure of these retained risk factors was assessed. Of each pair of correlating risk factors, only the one showing the more significant association with the dependent variable was retained for the multivariate model. Multivariate models were fitted by backward elimination procedures. According to Hosmer and Lemeshow  confounders were eliminated if they did not importantly change the estimates of the significant predictors. All two ways interactions were tested.
The sampling regimen resulted in a geographically representative sample population that was uniformly spread over the entire territory of Switzerland. Farms of origin of cattle shedding ESBL-producing Enterobacteriaceae are as well uniformly spread over the densely populated Swiss midlands as well as over the canton of Ticino in the south east of Switzerland. There were no cattle shedding ESBL-producing Enterobacteriaceae found originating from the canton of Valais in the south west of Switzerland.
ESBL-producing Enterobacteriaceae were detected in 48 (8.4%; 95% C.I. 6.3–11.1%) of the 571 tested animals. ESBL prevalence in different age classes, different production types and different animal movement activities in the farm of origin are summarized in Table 2. Results of the final multivariate logistic regression models applied for risk factor analysis are shown in Tables 3 and 4. Animals from within the age class ≤180 days were at a significantly higher risk of shedding ESBL-producing Enterobacteriaceae than animals from age classes 180 days to 1 year or 1 year to 2 years. Animals originating from farms with primary production type „dairy“ were at a 5.95 times greater risk of shedding ESBL-producing Enterobacteriaceae than animals originating from farms with primary production type „beef“. Finally, animals originating from farms with more than one animal movement per day per 100 animals were at a 2.37 times higher risk of shedding ESBL-producing Enterobacteriaceae than animals originating form farms with less than one animal movement per day100 animals.
In total, 48 isolates from 48 different animals showing the ESBL phenotype were further characterized. Species identification revealed 46 E. coli, one Enterobacter cloacae and one Citrobacter youngae (Figure 1). In view of β-lactam antibiotics, all 48 isolates were resistant to ampicillin (AM), the 1st-generation cephalosporin, cephalothin (CF) and the 3rd-generation cephalosporin, cefpodoxime (CPD) (Figure 1). Forty-five (93.8%) isolates were resistant to the 2nd-generation cephalosporin cefuroxime (CXM); one (2.1%) isolate to cefoxitin (FOX), 28 (58.3%) isolates to cefotaxime (CTX), 2 (4.2%) isolates to ceftazidime (CAZ), and 2 (4.2%) isolates to the 4th-generation cephalosporin cefepime (FEP). Seventeen strains (35.4%) showed resistance to amoxicillin-clavulanic acid (AMC). Besides β-lactam resistance, susceptibility to other classes of antibiotics was tested. Hereby, 26 (54.2%) isolates were resistant to gentamicin (GM), 27 (56.25%) to streptomycin (S), 21 (43.8%) to nalidixic acid (NA), 20 (41.7%) to ciprofloxacin (CIP), 36 (75.0%) to tetracycline (TE), 22 (45.8%) to chloramphenicol (C), and 30 (62.5%) to trimethoprim-sulfamethoxazole (SXT).
years. Symbols: black square, positive result or resistant to a specific antimicrobial agent; white square, negative result or susceptible to a specific antimicrobial. Abbreviations: AM, ampicillin (resistant ≤13 mm); AMC, amoxicillin-clavulanic acid (resistant ≤13 mm); CF, cephalothin (resistant ≤14 mm); CXM, cefuroxime (resistant ≤14 mm); FOX, cefoxitin (resistant ≤14 mm); CPD, cefpodoxime (resistant ≤17 mm); CTX, cefotaxime (resistant ≤14 mm); CAZ, ceftazidime (resistant ≤14 mm); FEP, cefepime (resistant ≤14 mm); GM, gentamicin (resistant ≤10 mm); S, streptomycin (resistant ≤11 mm); SXT, trimethoprim-sulfamethoxazole (resistant ≤10 mm); TE, tetracycline (resistant ≤11 mm); NA, nalidixic acid (resistant ≤13 mm); CIP, ciprofloxacin (resistant ≤15 mm); C, chloramphenicol (resistant ≤12 mm). Discrimination between “susceptible” and “resistant” was strictly according to CLSI interpretive criteria. It should be noted, however, that for clinical and therapeutic purposes, ESBL producers should generally be reported resistant to cephalosporins of all 4 generations and monobactams.
In this cross-sectional study, fecal samples of a geographically representative cattle subpopulation for Switzerland were sampled at slaughterhouse level to determine the occurrence of ESBL producing Enterobacteriaceae in the Swiss cattle population younger than 2 years, and to assess risk factors for shedding such organisms.
To assess the population prevalence of a pathogen or indicator organism on a national level, a geographically representative set of samples needs to be selected. Whilst this is easily achieved for samples taken on a farm level, where farms to be sampled can be determined in advance by applying a stratified randomization scheme, this is typically more difficult for samples taken at the slaughterhouse. This study demonstrated that the goal of a geographically representative survey could be achieved with a carefully planned sampling scheme involving the major cattle slaughterhouses and additional small abattoirs in areas disconnected from the main animal traffic.
To our knowledge, this is the first study on risk factors for shedding ESBL producing Enterobacteriaceae working with risk factors derived from animal movement data stored in a national AMD. Performing risk factor analysis with such data offered several advantages compared to risk factors derived form surveys, especially when the samples were collected at the abattoir and not on the farm. Getting information on animal movements and mortalities from 571 farms of origin of slaughtered animals via telephone or email surveys would be very time consuming. Furthermore, such information would be very imprecise compared to data from the Swiss AMD whose content is very accurate and complete.
The overall prevalence of cattle hosting ESBL producing Enterobacteriaceae found in this study (8.4%; 95% C.I. 6.3–11.1%) is slightly lower than found in previous, smaller scaled Swiss studies that reported prevalences of 13.7%  and 17.1% . Recent studies from other countries reported a very low (0.2%) prevalence in cattle in Korea  or even zero prevalence in cattle in Tunisia . Studies from European countries reported 35.4% (22.2–50.5% C.I. 95%) in North West England and North Wales  and 4.8% in France .
One of the significant risk factors for shedding ESBL producing Enterobacteriaceae obtained in the final multivariate model was age, with cattle over 6 months being at a considerably lower risk than calves (younger than 6 months) This is in accordance with a previous study of Geser et al.  who reported a overall prevalence of 13.7% in cattle as opposed to a prevalence of 25.3% among calves.
Animals from dairy farms were at a 5.95 times higher risk for hosting ESBL producing Enterobacteriaceae than animals from beef or fattening farms. This might be explained by differences between production types with respect to farming practices and antimicrobial compounds applied. In Switzerland, sales of cephalosporins have increased over the past years, especially the sales of 3rd and 4th generation cephalosporins for intramammary application . Snow et al.  reported that in North West England and North Wales farms that had used 3rd or 4th generation cephalosporins in livestock during the previous 12 months were nearly 4 times more likely to host ESBL E. coli. On Swiss dairy farms, calves not in consideration for breeding are either fattened on their farm of birth or they are sold to fattening farms at a very young age. Those fattened on the dairy farms are primarily fed with milk. For economic reasons, milk that cannot be put on the market because of elevated cell counts or because of recent antimicrobial treatments is often fed to calves. Moreover, ESBL hosting Enterobacteriaceae present on dairy farms might be transmitted to calves by the fecal-oral route. Calves later to be fattened on fattening farms leave their dairy farms very few weeks after birth and are thus at a lower risk for acquiring ESBL producing Enterobacteriaceae than animals staying on the dairy farms until slaughter. In comparison to dairy farms, beta-lactam antibiotics, especially 3rd and 4th generation cephalosporins, do not represent the predominantly used antimicrobial compounds on beef and fattening farms. The fact that among 40 animals originating from the canton of Valais no ESBL producers were found, might also be explained by the farming type, as meat production is predominant over milk production in this area.
The number of animal movements per farm per day per 100 animals is a factor related to introduction of new stock, and it was associated with presence of ESBL Enterobacteriaceae. Animals from farms with a high number of animal incoming movements in relation to total farm size were at a 2.37 times higher risk of hosting ESBL producing Enterobacteriaceae than animals from farms with a lower level of animal traffic. This is in agreement with Snow et al.  who reported that operating a closed farm policy reduced the risk of the farm having ESBL E. coli compared to farms that were open and did not quarantine new cattle.
The confirmation of relatively high rates of ESBL producers in cattle and the high diversity among the isolates are worrisome and indicate an established reservoir, especially in dairy farms. A prudent use of antibiotics, especially of 3rd and 4th generation cephalosporins, restrictions in feeding milk of treated cows to calves and management improvements to facilitate the operation of closed herd policies could represent modes of action towards reduction of ESBL prevalence in cattle. Experimental studies would be needed to assess the effectiveness of such measures. Moreover, this study showed that with a carefully planned sampling scheme involving the major cattle slaughterhouses and – in addition – small abattoirs in areas disconnected from the main animal traffic, geographically representative surveys can be achieved by taking random samples at the abattoir.
The authors thank the staff of the slaughterhouses for facilitating access to their premises and for the assistance during the collection of data. Moreover, we would like to thank Dr. Franceso Albanese and Dr. Margot Chastonnay for their help in the collection of the samples in the cantons of Ticino and Valais.
Conceived and designed the experiments: MR RS. Performed the experiments: NG HH RS. Analyzed the data: MR SS RS. Wrote the paper: MR SS RS.
- 1. Coque TM, Baquero F, Cantòn R (2008) Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Eurosurveill 13: 19044.
- 2. Bradford PA (2001) Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14: 933–951.
- 3. Cantòn R, Coque TM (2006) The CTX-M β-lactamase pandemic. Curr Opin Microbiol 9: 466–475.
- 4. Gniadkowski M (2001) Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 7: 597–608.
- 5. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S (1983) Transferable resistance to cefotaxime, cefoxitin, cefamamdole and defuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infect 11: 317–317.
- 6. Mesa RJ, Blanc V, Blanch AR, Cortés P, González JJ, et al. (2006) Extended-spectrum b-lactamase-producing Enterobacteriaceae in different environments (humans, food, animal farms and sewage). J Antimicrob Chemother 58: 211–215.
- 7. Geser N, Stephan R, Korczak BM, Beutin L, Hächler H (2012) Molecular identification of extended-spectrum-β-lactamase genes from Enterobacteriaceae isolated from healthy human carriers in Switzerland. Antimicrob Agents Chemother 56: 1609–1612.
- 8. Meunier D, Jouy E, Lazizzera C, Kobisch M, Madec JY (2006) CTX-M-1- and CTX-M-15-type beta-lactamases in clinical Escherichia coli isolates recovered from food-producing animals in France. Int J Antimicrob Agents 28: 402–407.
- 9. Wittum TE, Mollenkopf DF, Daniels JB, Parkinson AE, Mathews JL, et al. (2010) CTX-M-type expended-spectrum beta-lactamases present in Escherichia coli from the feces of cattle in Ohio, United States. Foodborne Path Dis 7: 1575–1579.
- 10. Geser N, Stephan R, Kuhnert P, Zbinden R, Kaeppeli U, et al. (2011) Fecal carriage of extended-spectrum ß-lactamase-producing Enterobacteriaceae in swine and cattle at slaughter in Switzerland. J Food Prot 74: 446–449.
- 11. Jensen LB, Hasman H, Agersø Y, Emborg HD, Aarestrup FM (2006) First description of an oxyimino-cephalosporin-resistant, ESBL-carrying Escherichia coli isolated from meat sold in Denmark. J Antimicrob Chemother 57: 793–794.
- 12. Hammad AM, Ahmed AM, Ishida Y, Shimamoto T (2008) First characterization and emergence of SHV-60 in raw milk of a healthy cow in Japan. J Vet Med Sci 70: 1269–1272.
- 13. Doi Y, Paterson DL, Egea P, Pascual A, López-Cerero L, et al. (2010) Extended-spectrum and CMY-type beta-lactamase-producing Escherichia coli in clinical samples and retail meat from Pittsburgh, USA and Seville, Spain. Clin Microbiol Infect 16: 33–38.
- 14. CLSI (2008) Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement. CLSI Document M100–S18, Wayne, PA.
- 15. Hosmer DW, Lemeshow S (1989) Applied logistic regression. Wiley and Sons, New York, NY, USA.
- 16. Geser N, Stephan R, Hächler H (2012) Occurrence and characteristics of extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae in food producing animals, minced meat and raw milk. BMC Vet Res 8: 21.
- 17. Tamang MD, Nam HM, Kim SR, Chae MH, Jang GC, et al. (2013) Prevalence and molecular characterization of CTX-M β-lactamase-producing Escherichia coli isolated from healthy swine and cattle. Foodborne Path Dis 10: 13–20.
- 18. Ben Sallem R, Ben Slama K, Sáenz Y, Rojo-Bezares B, Estepa V, et al. (2012) Prevalence and characterization of extended-spectrum beta-lactamase (ESBL)- and CMY-2-producing Escherichia coli Isolates from healthy food-producing animals in Tunisia. Foodborne Path Dis 9: 1137–1142.
- 19. Snow LC, Warner RG, Cheney T, Wearing H, Stokes M, et al. (2012) Risk factors associated with extended spectrum beta-lactame Escherichia coli (CTX-M) on dairy farms in North West England and North Wales. Prevent Vet Med 106: 225–234.
- 20. Hartmann A, Locatelli A, Amoureux L, Depret G, Jolivet C, et al. (2012) Occurrence of CTX-M producing Escherichia coli in soils, cattle, and farm environment in France (Burgundy Region). Front Microbiol 3: 83.
- 21. Anonymous ARCH-VET (2011) Swiss annual report on usage of antimicrobials in veterinary medicine and on monitoring antimicrobial resistance in food animals. Available: http://www.swissmedic.ch/marktueberwachung/00147/00644/index.html?lang=de. Accessed 2013 May 13.